Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTV NASDAQ:CING NASDAQ:FATE NASDAQ:MDWD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$7.88+0.1%$8.44$1.47▼$14.53$194.79M2.86311,872 shs87,641 shsCINGCingulate$4.57+2.2%$5.87$3.20▼$11.89$61.56M-0.81457,699 shs152,397 shsFATEFate Therapeutics$2.10-6.7%$1.50$0.91▼$2.46$244.78M2.132.06 million shs961,730 shsMDWDMediWound$16.58$16.79$14.90▼$22.50$213.05M0.2191,041 shs6,324 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics0.00%-14.64%-23.74%+56.77%+303.59%CINGCingulate0.00%-0.22%-18.28%-29.50%+22.13%FATEFate Therapeutics0.00%+30.06%+69.17%+38.89%+93.97%MDWDMediWound0.00%+1.10%-0.84%-5.63%-18.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTVArtiva Biotherapeutics$7.88+0.1%$8.44$1.47▼$14.53$194.79M2.86311,872 shs87,641 shsCINGCingulate$4.57+2.2%$5.87$3.20▼$11.89$61.56M-0.81457,699 shs152,397 shsFATEFate Therapeutics$2.10-6.7%$1.50$0.91▼$2.46$244.78M2.132.06 million shs961,730 shsMDWDMediWound$16.58$16.79$14.90▼$22.50$213.05M0.2191,041 shs6,324 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTVArtiva Biotherapeutics0.00%-14.64%-23.74%+56.77%+303.59%CINGCingulate0.00%-0.22%-18.28%-29.50%+22.13%FATEFate Therapeutics0.00%+30.06%+69.17%+38.89%+93.97%MDWDMediWound0.00%+1.10%-0.84%-5.63%-18.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTVArtiva Biotherapeutics 2.83Moderate Buy$39.00394.92% UpsideCINGCingulate 2.50Moderate Buy$28.33519.99% UpsideFATEFate Therapeutics 2.29Hold$5.13144.05% UpsideMDWDMediWound 2.25Hold$35.00111.10% UpsideCurrent Analyst Ratings BreakdownLatest CING, MDWD, FATE, and ARTV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026ARTVArtiva Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/26/2026CINGCingulate HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.005/22/2026CINGCingulate Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026FATEFate Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.005/19/2026CINGCingulate Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/19/2026FATEFate Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/13/2026FATEFate Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/12/2026ARTVArtiva Biotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $41.005/11/2026ARTVArtiva Biotherapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $40.005/11/2026ARTVArtiva Biotherapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$23.00 ➝ $40.005/8/2026ARTVArtiva Biotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $35.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTVArtiva Biotherapeutics$250K779.17N/AN/A$3.55 per share2.22CINGCingulateN/AN/AN/AN/A$1.40 per shareN/AFATEFate Therapeutics$6.65M36.81N/AN/A$1.54 per share1.36MDWDMediWound$16.96M12.56N/AN/A$3.40 per share4.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTVArtiva Biotherapeutics-$83.86M-$3.54N/AN/AN/AN/A-73.15%-62.74%8/5/2026 (Estimated)CINGCingulate-$22.45M-$4.23N/AN/AN/AN/A-365.15%-158.55%N/AFATEFate Therapeutics-$136.32M-$1.09N/AN/AN/A-2,056.79%-58.89%-39.39%8/11/2026 (Estimated)MDWDMediWound-$23.88M-$2.10N/AN/AN/A-140.80%-65.79%-30.16%5/27/2026 (Estimated)Latest CING, MDWD, FATE, and ARTV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2026Q1 2026MDWDMediWound-$0.65N/AN/AN/A$3.37 millionN/A5/14/2026Q1 2026CINGCingulate-$0.53-$0.95-$0.42-$0.95N/AN/A5/13/2026Q1 2026FATEFate Therapeutics-$0.29-$0.26+$0.03-$0.26$1.49 million$1.30 million5/8/2026Q1 2026ARTVArtiva Biotherapeutics-$0.88-$0.95-$0.07-$0.95N/AN/A3/18/2026Q4 2025CINGCingulate-$0.56-$0.84-$0.28-$0.84N/AN/A3/10/2026Q4 2025ARTVArtiva Biotherapeutics-$0.87-$0.84+$0.03-$0.84N/AN/A3/5/2026Q4 2025MDWDMediWound-$0.65-$0.56+$0.09-$0.56$2.09 million$1.87 million2/26/2026Q4 2025FATEFate Therapeutics-$0.27-$0.27N/A-$0.27$1.20 million$1.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARTVArtiva BiotherapeuticsN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/AFATEFate TherapeuticsN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTVArtiva BiotherapeuticsN/A8.168.16CINGCingulateN/A2.552.55FATEFate TherapeuticsN/A5.855.85MDWDMediWoundN/A2.332.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTVArtiva BiotherapeuticsN/ACINGCingulate41.31%FATEFate Therapeutics97.54%MDWDMediWound46.83%Insider OwnershipCompanyInsider OwnershipARTVArtiva Biotherapeutics21.40%CINGCingulate4.33%FATEFate Therapeutics4.74%MDWDMediWound9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTVArtiva Biotherapeutics8124.72 million19.43 millionN/ACINGCingulate2013.47 million12.89 millionNot OptionableFATEFate Therapeutics550116.56 million111.03 millionOptionableMDWDMediWound8012.85 million11.67 millionOptionableCING, MDWD, FATE, and ARTV HeadlinesRecent News About These CompaniesMediWound (MDWD) to Release Earnings on WednesdayMay 20, 2026 | americanbankingnews.comMediWound to Report First Quarter 2026 Financial ResultsMay 7, 2026 | globenewswire.comMediWound Shareholders Back Board, Auditor and CEO Bonus at 2026 Annual MeetingMay 6, 2026 | tipranks.comMediWound (NASDAQ:MDWD) Shares Pass Above Fifty Day Moving Average - What's Next?May 6, 2026 | marketbeat.comMediWound Ltd. (NASDAQ:MDWD) Given Consensus Rating of "Hold" by AnalystsApril 28, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Simulations Plus (SLP) and Mediwound (MDWD)April 16, 2026 | theglobeandmail.comNewly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound DebridementApril 13, 2026 | markets.businessinsider.comNewly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound DebridementApril 13, 2026 | globenewswire.comMediWound to Present New EscharEx® Data at Leading Wound Care ConferencesApril 7, 2026 | globenewswire.comMediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 MillionApril 2, 2026 | globenewswire.comMediWound Sets May 6, 2026 Shareholder Meeting to Vote on Board, Auditor and CEO BonusMarch 31, 2026 | theglobeandmail.comOppenheimer Sticks to Their Buy Rating for Mediwound (MDWD)March 13, 2026 | theglobeandmail.comMediWound Ltd. (NASDAQ:MDWD) Q4 2025 earnings call transcriptMarch 6, 2026 | msn.comMediWound outlines $24M–$26M 2026 revenue target while expanding EscharEx clinical programsMarch 5, 2026 | seekingalpha.comMediWound (MDWD) Q4 2025 Earnings Call TranscriptMarch 5, 2026 | finance.yahoo.comMediWound Files Annual Report on Form 20-FMarch 5, 2026 | globenewswire.comMediWound (MDWD) Reports Q4 Loss, Lags Revenue EstimatesMarch 5, 2026 | zacks.comMediWound Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 5, 2026 | globenewswire.comMediWound to Report Fourth Quarter and Full Year 2025 Financial ResultsFebruary 19, 2026 | globenewswire.comMediWound to Present at Upcoming Investor ConferencesFebruary 17, 2026 | globenewswire.comMediwound (MDWD) Gets a Buy from TD CowenJanuary 15, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000By Jeffrey Neal Johnson | May 12, 2026Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30%By Leo Miller | May 6, 2026Dollar at a 3-Year Low: 3 Exporters Quietly Printing MoneyBy Chris Markoch | May 9, 2026Nebius Breaks Out to All-Time Highs—Here's What's Driving It.By Ryan Hasson | May 5, 2026TFI Earnings Beat: Is This Stock the Freight Recovery King?By Jeffrey Neal Johnson | April 30, 2026CING, MDWD, FATE, and ARTV Company DescriptionsArtiva Biotherapeutics NASDAQ:ARTV$7.88 +0.01 (+0.13%) As of 10:38 AM EasternArtiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.Cingulate NASDAQ:CING$4.57 +0.10 (+2.24%) As of 10:37 AM EasternCingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Fate Therapeutics NASDAQ:FATE$2.10 -0.15 (-6.67%) As of 10:39 AM EasternFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.MediWound NASDAQ:MDWD$16.58 0.00 (0.00%) As of 10:43 AM EasternMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why BJ’s Wholesale Club Stock Could Be Ready for a Rebound After NVIDIA, Broadcom's Earnings Are Next—Here's What to Watch MarketBeat Week in Review – 05/18 - 05/22 Berkshire Sells Visa, Domino's, and Pool Corp: Should You Follow? Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Alphabet Just Unveiled Its Most Ambitious AI Lineup Yet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
